Press Releases BiomX Inc.

Equities

PHGE

US09090D1037

Market Closed - Nyse Other stock markets 21:10:00 10/05/2024 BST			5-day change	1st Jan Change
0.3546 ^USD	-1.50%		-7.63%	+26.64%

04-18	Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	CI
04-03	Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases	04-24	AQ
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)	04-23	AQ
BiomX Announces the Appointment of Susan Blum to its Board of Directors	04-18	AQ
BiomX : Introduction	04-04	PU
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure	04-04	AQ
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	04-03	AQ
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024	03-27	AQ
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing	03-18	AQ
BiomX : Material Agreement - Form 8-K	03-06	PU
BiomX : Introduction	03-06	PU
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing	03-06	AQ
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis	01-04	AQ
BiomX : CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 CONTENTS - Form 8-K	12-07	PU
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023	11-30	AQ
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	11-29	AQ
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update	11-14	AQ
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis	30/10/23	AQ
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference	27/10/23	AQ
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors	18/10/23	AQ
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	04/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BiomX Inc.

Equities

PHGE

US09090D1037

Press Releases

Filters